hey it's just one shmuck's opinion on a message board. To be clear I'm long with a large position. If you are banking on a transformative deal thsi year I just think it is a long shot. However I also think the company has options for financing until then short of a painful dilution (and it may not even come to that if the stock appreciates in advance of multiple readouts in 2020 which is entirely possible). One more valuation note - AGN bought a short acting phase 2 toxin for 195M plus milestones, which enables them to keep pace with ipsen which also has a short acting in the clinic. What is the value of a phase 3 long acting which has a larger market and which no competitor even is in the clinic with yet? A shitload more. So valuation alone can cause appreciation at this juncture IMO
Market Data 
Markets 
AI
